MétaCan
Menu
Back to cohort
Record W150401912 · doi:10.3833/pdr.v2011i6.1485

Boehringer Ingelheim Licenses Zealand Pharma’s Drug Candidates for Type 2 Diabetes and Obesity

2011· article· en· W150401912 on OpenAlexaboutno aff
Heather Cartwright

Bibliographic record

VenuePharmaDeals Review · 2011
Typearticle
Languageen
FieldMedicine
TopicPharmacology and Obesity Treatment
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineMilestoneType 2 diabetesPaymentObesityQuarter (Canadian coin)BusinessDiabetes mellitusInternal medicineFinanceEndocrinologyGeography

Abstract

fetched live from OpenAlex

Boehringer Ingelheim has licensed the global rights to Zealand Pharma’s dual-acting glucagon and GLP-1 (glucagon-like peptide-1) agonists for the treatment of type 2 diabetes and obesity. The collaboration includes ZP2929, which is expected to enter clinical development in the third quarter of 2011 and which some analysts believe could attain blockbuster status owing to its potential for obesity reduction. Zealand Pharma could receive total milestone payments of up to €376 M (US$539 M) for ZP2929 and payments of up to €41 M (US$58 M) during the first 2 years of the collaboration.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Other · Consensus signal: Other
Teacher disagreement score0.133
Threshold uncertainty score0.447

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.1330.069

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.082
GPT teacher head0.365
Teacher spread0.283 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2011
Admission routes1
Has abstractyes

Explore more

Same venuePharmaDeals ReviewSame topicPharmacology and Obesity TreatmentFrench-language works237,207